Showing results (161-170 of 260) with videos related to
Sort By:
Pageof 26
Health Bulletin|January 5, 2002
The chief scientist reports ... co-ordination of care on discharge from hospital into the community for patients with HIV/AIDS in LothianG O Huby, E R van Teijlingen, A M Porter, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|November 5, 1997
Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. The EARS Study. European Atherosclerosis Research StudyJ M Boer, C Ehnholm, H J Menzel, et al.Biochimica Et Biophysica Acta|August 24, 1995
Helix-helix interactions in reconstituted high-density lipoproteinsL Lins, R Brasseur, M De Pauw, et al.Journal of Neurochemistry|January 14, 1999
Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's diseaseT Pillot, M Goethals, J Najib, et al.Journal of Lipid Research|July 1, 1997
Determinants of postprandial lipemia in men with coronary artery disease and low levels of HDL cholesterolM Syvänne, P J Talmud, S E Humphries, et al.Journal of Neurochemistry|January 9, 2001
ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptideB Drouet, A Fifre, M Pinçon-Raymond, et al.Journal of Lipid Research|July 31, 1998
Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activitiesN Mero, A Van Tol, L M Scheek, et al.Biochimica Et Biophysica Acta|September 29, 1993
Synthetic model peptides for apolipoproteins. II. Characterization of the discoidal complexes generated between phospholipids and synthetic model peptides for apolipoproteinsJ Corijn, R Deleys, C Labeur, et al.European Journal of Pharmacology|February 29, 1996
Dual effects of oxidized low-density lipoprotein on immune-stimulated nitric oxide and prostaglandin release in macrophagesK E Matthys, C E Van Hove, P G Jorens, et al.Cancer Biotherapy & Radiopharmaceuticals|February 1, 1997
Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study GroupR O Dillman, M C Wiemann, M J Bury, et al.Pageof 26